BCD-250 / Biocad - LARVOL DELTA

COVER: Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) (clinicaltrials.gov) - P1/2 | N=50 | Terminated | Sponsor: Biocad | N=160 ➔ 50 | Trial completion date: Dec 2022 ➔ Apr 2022 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2022 ➔ Apr 2022; Sponsor's decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] A novel effective vaccine against SARSCoV2 based on recombinant adenoassociated virus serotype 5 (AAV5) (ESGCT 2021) - "It was shown that produced antibodies may neutralize the native SARSCoV2 virus with high efficacy which was complemented by functional memory Tcells response. Overall findings allow us to consider developed AAV5RBD vaccine candidate as an effective prophylaxis against COVID19."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVER: Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) (clinicaltrials.gov) - P1/2; N=160; Recruiting; Sponsor: Biocad

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases